Quick Answer
Adaptive Biotechnologies Corp reported Net Income Loss of -$59.50 million for the year ending 2025.
- Adaptive Biotechnologies Corp showed an increase of +62.7% in Net Income Loss from 2024 to 2025.
- This data is from Adaptive Biotechnologies Corp's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), Adaptive Biotechnologies Corp's Net Income Loss has declined by 38.9%.
- Historical annual values: Fiscal year 2025: -$59.50 million | Fiscal year 2024: -$159.49 million | Fiscal year 2023: -$225.25 million | Fiscal year 2022: -$200.19 million | Fiscal year 2021: -$207.28 million | Fiscal year 2020: -$146.23 million | Fiscal year 2019: -$68.61 million | Fiscal year 2018: -$46.45 million | Fiscal year 2017: -$42.83 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: